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a  b  s  t  r  a  c  t
In present  study  two  formulations  of Koﬂet  (syrup  and  lozenges)  were  evaluated  against
pyridine-induced  pharyngitis  in  rats.  Topical  application  of 10%  pyridine  showed  extrava-
sation  of  Evans  blue  stain  as  a characteristic  feature  of  on-going  inﬂammation.  In addition,
the  levels  of  TNF-  (p  <  0.01)  and  IL-6  (p  < 0.01)  were  signiﬁcantly  increased  compared  to
control.  Further,  histopathology  of the  pharyngeal  tissue  showed  submucosal  gland  hyper-
trophy, severe  mucosal  inﬂammation  characterized  by  presence  of mononuclear  cells  and
neutrophils along  with  haemorrhages  and  congestion;  however,  saline  applied  animals
(normal  control)  showed  normal  cytoarchitecture  of the  pharynx.  Interestingly,  pre-
treatment  with  dexamethasone  (1 mg/kg,  p.o.),  Koﬂet  lozenges  (KL)  (500  and  1000  mg/kg,
p.o.) and Koﬂet  syrup  (KS)  (2 and 4 ml/kg,  p.o.)  for 7 days  showed  signiﬁcant  and  dose
dependent  protection  by decreasing  the EB  dye  extravasation,  and  serum  levels  of TNF-
and IL-6.  In addition,  histopathological  ﬁndings  have  further  supported  the  protective  effect
of Koﬂet  formulations.  These  ﬁndings  suggest  that,  both  Koﬂet  syrup  and  Koﬂet  lozenges
are  highly  effective  in treating  non-infectious  type  of  pharyngitis.  Among  the  two  formula-
tions  KS  was  found  to be more  potent  than  KL, and  possible  mechanism  of  action  thought  to
be mediating  through  inhibition  of TNF-  and/or  phospholipids–arachidonic  acid  pathway.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe CC  B
. IntroductionThe inﬂammation of the mucus membrane of phar-
nx is termed as pharyngitis, commonly known as sore
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throat [1], it is the most common and frequent among
the upper respiratory tract diseases, which is accompa-
nied by fever and/or cough [2]. In United states, acute
pharyngitis accounts for about 1–2% of overall visits to
the  outpatient departments (OPD) and emergency depart-
ments  [3]. Pharyngitis is known to be commonly associated
with  symptoms such as hoarseness, sore throat, cough,
pain, difﬁculty in swallowing, airway obstruction, due to
pathologic  features like mucosal inﬂammation and sub-
mucosal oedema [4]. The frequent causes of pharyngitis
is mainly due to infections associated with virus, bacteria
is is an open access article under the CC BY-NC-ND license
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and rarely due to candidal, fungal and parasites (infectious
pharyngitis) [5], apart from infectious causes tracheal
intubation during medical procedures, smoking, snoring,
shouting, drugs such as ACE inhibitors, chemotherapy,
corticosteroids, exposure to pesticides and environmen-
tal factors such as pollution, temperature, humidity/air
conditioning are the non-infectious causative factors (non-
infectious pharyngitis) [6,7]. Additionally, the diseases
such as GERD (gastroesophasengeal reﬂux disease), thy-
roiditis  are well known to cause non-infectious type of
pharyngitis [8,9].
In  spite of many available treatment strategies for
pharyngitis, the side/adverse effects associated with them
always  made the scientists to think about the better, safe
medicine. However, currently there is a lack of rigor-
ous trials (both preclinical and clinical) for the treatment
of  non-infectious pharyngitis, one of the important fac-
tor  hampering the efforts in identifying the effective new
treatments is the lack of a suitable animal model for
non-infectious pharyngitis [5]. In this context, we  have
developed a novel animal model for non-infectious pharyn-
gitis  in rats using pyridine as an inducer [10], it was found
to  be useful in screening the beneﬁcial effect of synthetic,
plant based medicines in treating non-infectious pharyn-
gitis.  In continuation, the present study was  aimed to
evaluate Koﬂet syrup, Koﬂet lozenges against pyridine-
induced pharyngitis in rats.
2. Materials and methods
2.1.  Drugs and chemicals
Pyridine  (SD Fine chemicals, Bangalore), Dexametha-
sone (Zydus Cadila Healthcare Ltd., Mumbai), Koﬂet syrup
(The  Himalaya Drug Company, Bangalore), Koﬂet lozenges
(The  Himalaya Drug Company, Bangalore), TNF- and IL-6
ELISA  Kits (Krishgen Biosystems, Mumbai) were used for
the  study, other solvents and chemicals used were highly
pure  and of analytical grade purchased from HiMedia Lab-
orateries  Pvt. Limited, India.
2.2. Experimental animals
Inbred  Wistar rats (250–300 g) were used for the study.
The animals were maintained in polypropylene cages at
a  temperature of 25 ◦C ± 1 ◦C and relative humidity of
45–55% in a clean environment under 12:12 h light–dark
cycle. The animals had free access to food pellets (Pranav
Agro Industry, Bangalore, India) and puriﬁed water.
All  the experimental protocols were approved by Insti-
tutional Animal Ethics Committee (IAEC) of The Himalaya
Drug  Company and were conducted according to the guide-
lines  of Committee for the Purpose of Control and Supervi-
sion  of Experimentation on Animals (CPCSEA), India.
2.3.  Experimental protocol2.3.1.  Grouping and treatment schedule
Wistar rats (250–300 g) were divided into seven groups
(G-I to G-VII, n = 10), G-I and G-II served as normal control
and  positive control; G-III served as standard and receivedReports 1 (2014) 293–299
dexamethasone (1 mg/kg, p.o.), G-IV and V have received 2
and  4 ml/kg, p.o., doses of Koﬂet syrup, while G-VI and VII
have  received Koﬂet lozenges at 500 and 1000 mg/kg, p.o.
doses  respectively for 7 days.
2.3.2. Induction of pharyngitis
On  seventh day after administration of last dose of
assigned treatments, EB dye (30 mg/kg, i.v.) was adminis-
tered to all the animals via lateral tile vein. Ten minutes
after the administration of EB dye, 10% pyridine was
applied to the pharyngeal mucosa. In short, The tongue
was  slightly pulled out and pharynx area was  opened deep
into  the oral cavity with the help of blunt forceps and the
pyridine was applied with the help of cotton swab, gently
for  5 s at each time point, for three times (approximately
50 l). For G-I saline solution was  applied similarly, since
the  pyridine solution was prepared in saline [10].
2.3.3. Induction of pharyngitis
After  60 min  of pyridine/saline application, all the ani-
mals  were sacriﬁced by exsanguination and the head
portion was perfused with heparinised saline (40 IU/ml)
to  expel the intravascular EB dye. Then, the bilateral mus-
culus  masseter of the rat was incised and the lower jaw
was  removed to enable the extirpation of the pharynx. The
portion  of pharynx ranging from the caudal end of the soft
palate  to the epiglottis was isolated and weighed (approx-
imately 40–50 mg).
The EB dye in the tissue was  extracted in formamide
at 55 ◦C for 24 h and determined spectrophotometrically
at 620 nm,  the tissue dye content was  expressed as micro-
gram  of dye per gram of wet weight of the tissue (g/g).
Parallel to these experiments another set of experiments
were run without administration of EB dye and the tis-
sue  samples collected were subjected to histopathological
evaluation.
The blood samples were collected and serum was sepa-
rated for the estimation of proinﬂammatory cytokines such
as  tumour necrosis factor alpha (TNF-) and interleukin-
6 (IL-6). These estimations were performed as per the
user  manual provided along with the respective ELISA Kits
(Krishgen  Biosystems, Mumbai, India).
3. Results
The polyherbal formulations, Koﬂet syrup and Koﬂet
lozenges manufactured by Ms.  The Himalaya Drug Com-
pany,  Bangalore are well known for their beneﬁcial effect
in  the treatment of pharyngitis and other upper respiratory
tract diseases. The test formulations used in the present
study (Koﬂet syrup and Koﬂet lozenges) are well known
for  the treatment of both infectious and non-infectious
types of pharyngitis. However, there is a lack of scien-
tiﬁc evidence related to their beneﬁcial effect with respect
to  non-infectious type of pharyngitis. Incidentally, there
is  a paucity of scientiﬁc literature and reports related
to screening models for non-infectious type of pharyngi-
tis, hence in our previous study we  have standardized a
novel  experimental animal model for non-infectious type
of  pharyngitis in rat using pyridine as a inducer [10]. In the
present  study, we have evaluated KS (2 and 4 ml/kg, p.o.)











lFig. 1. Standard curve for Evans Blue.
nd KL (500 and 1000 mg/kg, p.o.) against pyridine-induced
haryngitis in rats using dexamethasone (1 mg/kg, p.o.) as reference standard. The doses of KS and KL were selected
y  extrapolating human dose to animals dose, while dexa-
ethasone dose was selected based on our previous study.
ig. 2. Effect of Koﬂet formulations on pyridine-induced pharyngitis in rats. Note
alues  are expressed as mean ± SEM (n = 6); all the groups were statistically com
ompare  to control, *p < 0.01 compare to positive control (10% pyridine).
ig. 3. Percentage inhibition graph of Koﬂet formulations on pyridine-induced p
ozengesReports 1 (2014) 293–299 295
All  the treatments were given for 7 days, on day-7 after
administration of EB dye (30 mg/kg, i.v.) the pharyngeal tis-
sue  was separated and the quantity of EB dye present in the
pharyngeal tissue was quantiﬁed by using standard curve
for  EB dye (Fig. 1). In 10% pyridine per se applied animals
severe extravasation of EB dye was observed which is due to
inﬂammation  of pharynx, however normal control animals
applied  with saline showed very minimal/no extravasation
of  EB dye. Interestingly, dexamethasone (1 mg/kg, p.o.), KS
(2  and 4 ml/kg, p.o.) and KL (500 and 1000 mg/kg, p.o.)
treated animals showed negligible/no blue ting, as an indi-
cation  of their protective effect against pyridine-induced
damage and the morphology of pharyngeal tissues were
comparable with that of normal control (Figs. 2–4).
Besides EB dye test, serum levels of proinﬂammatory
cytokines (TNF- and IL-6) and histopathological evalua-were in line with the EB dye test, the serum levels of
TNF- (p < 0.01) and IL-6 (p < 0.01) were found to be sig-
niﬁcantly increased in 10% pyridine applied group when
: Dexa – dexamethasone, KS – Koﬂet syrup, KL – Koﬂet lozenges. All the
pared by ANOVA followed by Tukey’s multiple comparison. #p < 0.001
haryngitis. Note: Dexa – dexamethasone, KS – Koﬂet syrup, KL – Koﬂet
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Fig. 4. Effect of Koﬂet formulations on pyridine-induced morphological damage of rat pharynx. The images of rat oral cavity demonstrates the effect of
pyridine  application on morphology of pharynx. The induction of pharyngitis was  conﬁrmed by administering Evans Blue dye and the intensity of blue
colour  in the target area (pharynx) is considered as a direct measure of inﬂammation (pharyngitis). The normal control shows negligible or no blue tinge,
positive  control with intense blue tinge is a sign of severe induction of pharyngitis. The reference drugs dexamethasone (1 mg/kg, i.v.), diclofenac (5 mg/kg,
i.v.)  and test drugs Koﬂet syrup (4 ml/kg, p.o.) and Koﬂet lozenges (1000 mg/kg, p.o.) treated groups with very minimal blue tinge indicates their protective
effect  against pyridine-induced pharyngitis.
Fig. 5. Effect of Koﬂet formulations on pyridine-induced elevated serum TNF- levels in rats. Note: Dexa – dexamethasone. Values are expressed as
mean  ± SEM (n = 6); all the groups were statistically compared by ANOVA followed by Tukey’s multiple comparison. #p < 0.001 compare to control, *
p  < 0.05, ** p < 0.01 compare to positive control (10% pyridine).
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nig. 6. Effect of Koﬂet formulations on pyridine-induced elevated seru
ean  ± SEM (n = 6); all the groups were statistically compared by ANOVA f
*p  < 0.01 compare to positive control (10% pyridine).
ompared to normal control. Exceptionally, dexametha-
one (1 mg/kg, p.o.) (p < 0.01), Koﬂet lozenges (KL) (500 and
000  mg/kg, p.o.) (p < 0.01) and Koﬂet syrup (KS) (2 and
 ml/kg, p.o.) (p < 0.01) treatments for 7 days has brought
own the serum levels of TNF- and IL-6 near to normal
ontrol and thus showed signiﬁcant protection against 10%
yridine-induced elevation of proinﬂammatory cytokines
Figs.  5 and 6).
Furthermore, histopathology of the pharynx showed
ypertrophy of submucosal glands, severe inﬂammation
f the mucosa characterized by the presence of mono-
uclear cells, neutrophils, ruptured mucosal glands along
ith  haemorrages and congestion in pyridine per se applied
ig. 7. Protective effect of Koﬂet formulations on against pyridine-induced histo
pplication  in rats. (A) Normal control – normal cytoarchitecture of pharynx, (B) p
ass  of inﬂammatory cells, ruptured mucosal glands as signs of severe inﬂammat
D)  Koﬂet syrup (2 ml/kg, p.o.) – mild hypertrophy of mucosal glands and hemm
hanges, (F) Koﬂet lozenges (500 mg/kg, p.o.) – mild hypertrophy of mucosal g
egligible  inﬂammatory changes.levels in rats. Note: Dexa – dexamethasone. Values are expressed as
 by Tukey’s multiple comparison. #p < 0.001 compare to control, *p < 0.05,
animals,  however normal control animals applied with
saline  showed normal cytoarchitecture of the pharynx.
Interestingly, dexamethasone (1 mg/kg, p.o.), KS (4 ml/kg,
p.o.)  and KL (1000 mg/kg, p.o.) treated animals showed
only mild haemorrhages with mild hypertrophy of mucus
glands.  Exceptionally, mucosal gland rupture, haemor-
rhages and congestions were found to be completely absent
in  dexamethasone (1 mg/kg, p.o.), (4 ml/kg, p.o.) and KL
(1000  mg/kg, p.o.) treated animals (Fig. 7).Noteworthy, KS (2 and 4 ml/kg, p.o.) and KL (500 and
1000 mg/kg, p.o.) were found to be equally potent and com-
parable  with reference standard dexamethasone (1 mg/kg,
p.o.).
logical changes in rat pharynx. Histopathology of Pharynx after pyridine
ositive control – showing hypertrophy of mucosal glands, haemorrhages,
ion, (C) dexamethasone (1 mg/kg, p.o.) – negligible signs of inﬂammation,
orrhages, (E) Koﬂet syrup (4 ml/kg, p.o.) – very negligible inﬂammatory
lands and haemorrhages, (G) Koﬂet lozenges (1000 mg/kg, p.o.) – very
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The ﬁndings have revealed that, pre-treatment with
dexamethasone (1 mg/kg, p.o.), KS (2 and 4 ml/kg, p.o.) and
KL  (500 and 1000 mg/kg, p.o.) for 7 days could be highly
beneﬁcial in preventing the pyridine-induced pharyngitis
in  rats.
4. Discussion
Recently a paper published by Bertold et al., stated that
currently there is a lack rigorous trials (both preclinical
and clinical) relevant to non-infectious pharyngitis and it
is  mainly due to lack of suitable preclinical animal model
for  non-infectious pharyngitis [5]. In this context, in our
previous studies we have developed a novel experimental
animal for non-infectious pharyngitis using various con-
centrations of pyridine in rats [10].
Pyridine is one of the commonly used reagent and
mainly used as a precursor for the synthesis of various
pharmaceuticals (sulfapyridine, tripelennamine, mepyra-
mine)  and agrochemicals (herbicides, pesticides), also in
in  vitro DNA synthesis [11]. Pyridine is known to be
absorbed through the skin and mucus membrane, also irri-
tates  eyes, nose and respiratory tract. Acute exposure to
pyridine  can lead to headaches, dizziness, nausea, anorexia,
dermatitis. While chronic exposure to pyridine results in
health  hazards such as CNS depression, hepatotoxicity,
nephrotoxicity, neurotoxicity, genotoxicity and GI tract
damage  [12].
While  standardizing the model we have used both
dexamethasone (corticosteroid) and diclofenac (NSAID) as
reference  standards against pyridine-induced pharyngitis
and  we found that dexamethasone was more potent and
reliable,  and hence in the present study we have used dexa-
methasone as a reference standard [10].
Noteworthy, dexamethasone is commonly used for
treating the non-infectious type of pharyngitis, by consid-
ering  the potency and therapeutic application in treating
non-infectious pharyngitis; in the present study we  have
chosen  dexamethasone as reference standard.
Pyridine in known to cause mucus membrane damage
and irritation of respiratory tract upon exposure [12–14],
in  the present study after 10% pyridine application to the
pharyngeal region various parameters were evaluated to
conﬁrm  and quantify the extent of inﬂammation. It is well
known  that, inﬂammation is the response of the tissue
to  injury which is characterized by increased blood ﬂow
and  vascular permeability along with accumulation of ﬂuid
(extravasation), leukocytes and inﬂammatory mediators
such as cytokines [15]. Extravasation is one of the impor-
tant  hall marks of inﬂammation and in literature it was
commonly evaluated by means of EB dye test, the quantity
of  EB dye present in the pharyngeal tissue is considered
to be a direct measure to rate the severity of inﬂamma-
tion [16]. Also, the acute phase pro-inﬂammatory cytokines
such  as TNF- and IL-6 were estimated to see the extent of
inﬂammation.The  cytokines are the groups of cell derived polypep-
tides which play a pivotal role in orchestrating the
inﬂammatory response by increasing the cellular inﬁltra-
tion  (leucocyte recruitment), cellular activation (mast cells,Reports 1 (2014) 293–299
endothelial  cells, tissue macrophages, etc.) and systemic
response to inﬂammation (fever, hypotension, cachexia,
leucocytosis, etc.) [15], TNF- and IL-6 are considered
to be the most potent proinﬂammatory cytokines and
they  are well proved to play an important role in the
acute phase inﬂammation and hence in present study
serum levels of TNF- and IL-6 were estimated along with
histopathological evaluation of pharyngeal tissue after
pyridine application.
In  experimental ﬁndings, 10% pyridine per se applied
animals showed severe extravasation of EB dye, also
the  serum levels of TNF- (p < 0.01) and IL-6 (p < 0.01)
were found to be signiﬁcantly increased in 10% pyri-
dine applied group when compared to normal control.
Additionally, histopathology of the pharynx showed hyper-
trophy  of submucosal glands, severe inﬂammation of the
mucosa  characterized by the presence of mononuclear
cells, neutrophils, ruptured mucosal glands along with
haemorrhages and congestion in 10% pyridine applied
group when compared to normal control.
Interestingly, one week pre-treatment with KS (2 and
4  ml/kg, p.o.), KL (500 and 1000 mg/kg, p.o.) and dexa-
methasone (1 mg/kg, p.o.) showed signiﬁcant and dose
dependent decrease in EB dye extravasation, and also
showed signiﬁcant decrease in serum levels of TNF- and
IL-6  compared to pyridine per se applied animals.
In similar lines, histopathological ﬁndings have showed
only mild haemorrhages with mild hypertrophy of mucus
glands  in KS (2 ml/kg, p.o.) and KL (500 mg/kg, p.o.)
treated animals. Exceptionally, the pathological changes
were  found to completely absent in dexamethasone
(1 mg/kg, p.o.), KS (4 ml/kg, p.o.) and KL (1000 mg/kg,
p.o.) treated animals. Furthermore, we  thought pyridine
induced pharyngitis involves multiple mechanisms such
as  enhanced expression of TNF- (which further increases
IL-6 levels), stimulation of phospholipid–arachidonic acid
pathway  through activation of phospholipase A2 and
cyclooxygenases (COX’s) and hence both dexamethasone
and diclofenac have showed protective effect against
pyridine-induced pharyngitis. In line with the above state-
ment,  in the present study KS and KL have showed
signiﬁcant protection against pyridine-induced pharyngi-
tis  and possible mechanism behind the protective effect
of  KS and KL were thought to be associated with mul-
tiple mechanisms such as inhibition of TNF- and/or
phospholipid–arachidonic acid pathway.
5. Conclusion
These ﬁndings suggest that, both Koﬂet syrup and
Koﬂet lozenges are highly effective in treating non-
infectious type of pharyngitis. Furthermore, KS was found
to  be more potent than KL in tested doses and possible
mechanism of action thought to be mediating through
inhibition of TNF- and/or phospholipids–arachidonic acid
pathway.Conﬂicts of interest
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